Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

SpectraCure

0.17 SEK

-2.91 %

Less than 1K followers

SPEC

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.91 %
-14.45 %
-0.95 %
-61.16 %
-84.57 %
-67.76 %
-94.37 %
-97.83 %
-73.24 %

SpectraCure operates in the medical technology sector. The company specializes in research and development of medical technology systems used for the treatment of prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internal solid tumors of various types. The largest operations are found in the Nordic market. The company has its headquarters in Lund.

Read more
Market cap
68.41M SEK
Turnover
76.44K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.2.
2026

Annual report '25

27.5.
2026

Interim report Q1'26

All
Press releases
ShowingAll content types
Regulatory press release2/23/2024, 8:30 AM

SpectraCure takes the next step in the work with the new clinical study

SpectraCure
Press release1/23/2024, 10:45 AM

A well-accomplished annual audit in accordance with ISO 13485:2016

SpectraCure
Regulatory press release12/19/2023, 7:30 AM

Expert group comments on results of ongoing study

SpectraCure

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release11/16/2023, 2:30 PM

SpectraCure has decided to seek approval for a clinical study of primary prostate cancer

SpectraCure
Press release10/6/2023, 12:30 PM

SpectraCure strengthens presence among urologists

SpectraCure
Regulatory press release6/27/2023, 9:30 AM

SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®

SpectraCure
Regulatory press release12/7/2022, 10:00 AM

SpectraCures signs Letter of Intent with Cheplapharm

SpectraCure
Regulatory press release8/30/2022, 9:00 AM

SpectraCure: Patent regarding the new generation of treatment systems approved in Europe

SpectraCure
Regulatory press release6/7/2022, 12:15 PM

SpectraCure has been approved a grant from EU of € 125,000

SpectraCure
Press release5/16/2022, 9:00 AM

A new Board has been installed at SpectraCure

SpectraCure
Regulatory press release4/15/2021, 12:00 PM

The Nomination Committee's proposal for election of board members in SpectraCure AB

SpectraCure
Regulatory press release3/5/2021, 9:30 AM

SpectraCure: Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer

SpectraCure
Regulatory press release9/16/2020, 2:48 PM

SpectraCure: Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!

SpectraCure
Regulatory press release6/26/2020, 2:30 PM

SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue

SpectraCure
Regulatory press release4/7/2020, 11:00 AM

Patent application enters PCT phase, SpectraCure ensures development and work

SpectraCure
Regulatory press release3/12/2020, 12:35 PM

The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020

SpectraCure
Regulatory press release1/17/2020, 3:50 PM

A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.

SpectraCure
Regulatory press release11/26/2019, 4:56 PM

SpectraCure: Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27

SpectraCure
Regulatory press release11/13/2019, 3:20 PM

SpectraCure's main owner subscribes in full for his share

SpectraCure
Regulatory press release11/12/2019, 3:00 PM

SpectraCure AB Quarterly Report (1 July to 30 September) 2019

SpectraCure
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.